Results 81 to 90 of about 12,025 (204)

Lower density of calretinin‐immunopositive neurons in the putamen of subjects with schizophrenia

Journal of Anatomy, Volume 246, Issue 4, Page 505-516, April 2025.
Recent neuroimaging and histological studies highlight the striatum as a key area involved in SCH, but the specific impairment of neuronal subtypes in subcortical structures is not fully understood. This study is the first detailed investigation of neuroanatomical changes in the putamen in SCH, specifically examining the density of calretinin ...
Paz Kelmer, Paulina Hoppa, Erzsébet Frank, Teadora Tyler, Istvan Adorjan   +4 more
wiley   +1 more source

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. [PDF]

Cochrane Database Syst Rev, 2023
Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E, Kew KM.   +6 more
europepmc   +1 more source

Antipsychotics‐Induced Hyposalivation Mediated by Impaired Salivary Ca2+ Signaling

Oral Diseases, EarlyView.
ABSTRACT Objectives Antipsychotic‐induced salivary dysfunction such as hyposalivation is a prevalent clinical challenge that severely compromises oral health and quality of life. Although typical and atypical antipsychotics have their therapeutic target in the central nervous system, their direct molecular mechanisms within the salivary glands remain ...
Chaelin Chung, Soohyun Kim, Yoo‐Bin Kim, Hee‐Kyung Park, Se‐Young Choi   +4 more
wiley   +1 more source

Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease

Therapeutic Advances in Respiratory Disease, 2015
Exacerbations of chronic obstructive pulmonary disease (COPD) have important consequences for lung function, health status and mortality. Furthermore, they are associated with high economic costs, predominantly related to hospitalization. They are managed acutely with short-acting bronchodilators, systemic corticosteroids or antibiotics; however, a ...
openaire   +3 more sources

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β₂-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Ismaila AS.   +7 more
europepmc   +1 more source

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD

International Journal of COPD, 2016
Gregory Feldman,1 François Maltais,2 Sanjeev Khindri,3 Mitra Vahdati-Bolouri,3 Alison Church,4 William A Fahy,3 Roopa Trivedi4,5 1S. Carolina Pharmaceutical Research, Spartanburg, SC, USA; 2Institut universitaire de cardiologie et de pneumologie ...
Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy WA, Trivedi R   +6 more
doaj  

Ion Channel Dysfunction and Therapeutic Targeting in Salivary Gland Disorders

Oral Diseases, EarlyView.
ABSTRACT Objective Salivary gland hypofunction and xerostomia represent major clinical complications of radiation therapy, autoimmune disorders such as Sjögren's disease, and inherited epithelial ion transport defects. This review integrates current knowledge on ion channel dysfunction as a central mechanistic driver of salivary gland pathology and ...
Tarek Mohamed Abd El‐Aziz, Shankara N. Varadarajan, Viktor Drel, Prakash Arullampalam, Mahmoud I. Shoulkamy, Ahmed Al‐Sabi, Brij B. Singh   +6 more
wiley   +1 more source

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan. [PDF]

Front Physiol, 2023
Umeda A, Shimada H, Yamane T, Mochizuki T, Inoue Y, Tsushima K, Miyagawa K, Mochida A, Takeda H, Okada Y, Masaki K, Matsusaka M, Fukunaga K.   +12 more
europepmc   +1 more source

Mechanisms reducing parasympathetic activity in chronic hypoxia

The Journal of Physiology, EarlyView.
Abstract figure legend Parasympathetic activity is reduced in chronic hypoxia, but the underlying mechanism(s) are unclear. Using β‐adrenergic blockade to isolate parasympathetic control of heart rate at sea level and after 9‐12 days at high altitude, we investigated whether (i) chemoreflex activation, (ii) increased pulmonary ventilation and/or (iii ...
Lauren E. Maier, Andrew Douglas, Katharine Foster, Elliott J. Jenkins, Liam D. Corr, Peter Rasmussen, James Anholm, Travis D. Gibbons, Phil N. Ainslie, Mike Stembridge, Christoph Siebenmann   +10 more
wiley   +1 more source

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β₂-Agonist Dual Therapy in a Primary Care Setting in England. [PDF]

Int J Chron Obstruct Pulmon Dis, 2022
Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.   +8 more
europepmc   +1 more source